Donepezil and Embelin loaded Nanostructured lipid carriers for direct brain delivery as an intervention for Alzheimer’s disease: Formulation design, Optimization and Evaluation

Donepezil hydrochloride (DPL) and Embelin (EMB) loaded Nanostructured Lipid Carriers (NLCs) have been developed and optimized to achieve optimal drug loading, safer nasal delivery, effective neuronal/cell uptake, enhanced brain accessibility, controlled release, and desired therapeutic effect. Molecular docking studies demonstrated that both drugs bind effectively to AchE with interaction energies of -48.5319 and − 65.7525, respectively, indicating a synergistic approach. The hydrophobic interactions with target proteins facilitate the transportation of drugs through brain hydrophobic channels to provide a desired pharmacological response. N2a cell line investigation advised a 1:1 ratio of DPL and EMB to have the greatest possible synergistic effect based on the MTT assay. NLCs were fabricated by hot emulsification probe sonication method and optimized using QbD-based Central Composite Rotatable Design (CCRD). Optimized NLCs with a diameter of 180.2 nm were suitable for axonal uptake. A low PDI score of 0.37 and ZP of -12 mV indicated a uniform monodisperse system with persistent and stable dispersion properties.

The NLCs demonstrated sustained drug release, DPL released at 90.72 ± 1.00 percent and EMB at 81.30 ± 0.52 percent in 24 hours. The Korsemeyer-Peppas model proved to be the most accurate fit due to its strong correlation. Ex vivo permeation and CLSM studies revealed superior goat nasal mucosa penetration of NLCs over suspension with a higher fluorescence level, up to 35 µm. NLCs treated nasal mucosa exhibited no erosion or interstitial gaps in the histopathological study. Moreover, NLCs were nontoxic and non-irritating, with a HET CAM score of 0.68 ± 0.05, indicating safe nasal delivery. The cellular uptake study showed a preponderance of the NLCs in the Cell’s cytoplasm, indicating ready uptake by N2a cells. Hence, intranasal therapy with the DPL and EMB-loaded NLCs could be a practical and promising implementation. Further in vivo, and clinical studies will be required to establish the formulation’s efficacy in treating Alzheimer’s disease (AD).

2.1. Materials

DPL and EMB were acquired from Sun Pharma Research Lab (Gurgaon, India) and Sigma-Aldrich (St. Louis, USA), respectively. Stearic acid, Oleic acid, Black seed oil, Castor oil, Tween 80, and Tween 20 were obtained from SD—fine Chemicals, Ltd. (Mumbai, India). Compritol 888 ATO, Precirol ATO5, Gelucire, Geleole, Thymoquinone, Capryol 90, Cremophore EL, Solutol HS 15, and Poloxamer 407 were acquired from Gattefose India Pvt. Ltd., Mumbai, India. All the additional chemicals were procured from Northern laboratory implements, Sigma-Aldrich, and SD Fine Chemicals, India. Milli-Q grade water (Millipore, Molsheim, France) was utilized for the study. The chemicals employed for fabricating NLCs were analytically graded.

Download the full study Preprint here: Donepezil and Embelin loaded Nanostructured lipid carriers for direct brain delivery as an intervention for Alzheimer’s disease Formulation design, Optimization and Evaluation – Preprint

or read it here